日本利用医保索赔数据开展疫苗安全主动监测:VENUS研究
日本九州大学于2021年启动VENUS研究,利用医保索赔数据建立疫苗安全主动监测系统。与美国VSD相比,VENUS在数据标准化、免疫记录完整性、伦理审查流程和人群代表性方面存在差距,需提升数据准确性、实时分析能力和人群覆盖范围。
要点
- VENUS研究利用医保索赔数据建立日本疫苗安全主动监测系统。
- 与美国VSD相比,VENUS在数据碎片化、免疫记录缺失和伦理审查方面存在挑战。
- 需增强数据准确性、实时分析能力并扩大人口覆盖以改善疫苗安全监测。
核心结论
- VENUS研究利用医保索赔数据建立日本疫苗安全主动监测系统,但与VSD相比在数据标准化、免疫记录完整性、伦理审查和人群代表性方面存在显著挑战。
- 为改善日本疫苗安全监测,VENUS需提升数据准确性、整合实时分析能力并扩大人口覆盖范围,以避免不必要的免疫规划中断。
研究设计与样本
- VENUS研究由九州大学于2021年启动,利用医保索赔数据建立疫苗安全主动监测的试点系统。
- 研究对比了VENUS与美国VSD在数据来源、免疫追踪、伦理审查和网络基础设施等方面的差异。
主要发现
- VSD依托11个管理式医疗组织的标准化数据,实现精准免疫追踪、集中病历审查和近实时快速循环分析。
- VENUS依赖碎片化的市政数据,缺乏全面免疫记录,病历审查需医院特定机构审查委员会批准。
- VENUS通过匿名化和安全物理传输保障数据安全,但缺乏VSD的稳健网络基础设施。
- VENUS数据主要代表国民健康保险和后期高龄者医疗制度,限制了对日本 broader 人群的推广性。
临床怎么用
- 预防医学与公共卫生医生应了解VENUS作为日本疫苗安全主动监测试点系统的数据来源和覆盖范围局限。
- 在解读日本疫苗安全信号时,需考虑VENUS数据主要来自国民健康保险和后期高龄者医疗制度,可能不representative全人群。
- 推动疫苗安全监测体系完善时,可参考VSD的标准化数据、集中审查和实时分析经验,但需结合本地数据基础设施。
局限性
- VENUS依赖碎片化的市政数据,缺乏全面免疫记录。
- 病历审查需医院特定机构审查委员会批准,形成后勤障碍。
- 数据主要代表国民健康保险和后期高龄者医疗制度,限制人群推广性。
- 缺乏VSD的稳健网络基础设施和近实时分析能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate vaccine safety monitoring requires the integration of both passive and active surveillance systems. In Japan, the development of active surveillance systems has been limited, leading to delays in timely vaccine safety assessments. To bridge this gap, Kyushu University initiated the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study in 2021. The study utilizes health insurance claims data to establish a pilot active surveillance system for vaccine safety in Japan. However, significant challenges remain when comparing the VENUS study to the Vaccine Safety Datalink (VSD) in the United States. The VSD benefits from standardized data collected across 11 managed care organizations, enabling precise immunization tracking, centralized medical chart reviews, and near real-time rapid cycle analysis using secure systems. In contrast, the VENUS study relies on fragmented municipal data, lacks comprehensive immunization records, and faces logistical barriers such as requiring hospital-specific Institutional Review Board approval for medical chart reviews. While data security in the VENUS study is maintained through anonymization and secure physical transfer methods, it lacks the robust network infrastructure employed by the VSD. Furthermore, VENUS study data primarily represent National Health Insurance and the latter-stage elderly healthcare insurance system, which limits their generalizability to Japan's broader population. To improve vaccine safety monitoring in Japan, the VENUS study must overcome these challenges by enhancing data accuracy, incorporating real-time analytical capabilities, and broadening its demographic scope. Addressing these issues is essential to ensure reliable vaccine safety assessments and prevent unnecessary interruptions to immunization programs.
引用
- Katsuta T, Sato S, Kawazoe Y, et al. Active vaccine safety monitoring system using health insurance claims data in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Vaccine. 2026. PMID: 41512504. doi:10.1016/j.vaccine.2026.128209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。